These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 21099368

  • 1. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.
    Liu G, Dou S, Baker S, Akalin A, Cheng D, Chen L, Rusckowski M, Hnatowich DJ.
    Cancer Biol Ther; 2010 Oct 15; 10(8):767-74. PubMed ID: 21099368
    [Abstract] [Full Text] [Related]

  • 2. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.
    Liu G, Dou S, Pretorius PH, Liu X, Chen L, Rusckowski M, Hnatowich DJ.
    Q J Nucl Med Mol Imaging; 2010 Jun 15; 54(3):333-40. PubMed ID: 20639818
    [Abstract] [Full Text] [Related]

  • 3. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.
    Liu G, Dou S, He J, Liu X, Rusckowski M, Hnatowich DJ.
    Eur J Nucl Med Mol Imaging; 2007 Feb 15; 34(2):237-46. PubMed ID: 17021815
    [Abstract] [Full Text] [Related]

  • 4. Pretargeting the masses: a means of improving and mainstreaming targeted molecular delivery?
    Nguyen V, Conyers JM, Mintz A.
    Cancer Biol Ther; 2010 Oct 15; 10(8):775-9. PubMed ID: 20935465
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue.
    Liu G, Dou S, Mardirossian G, He J, Zhang S, Liu X, Rusckowski M, Hnatowich DJ.
    Clin Cancer Res; 2006 Aug 15; 12(16):4958-64. PubMed ID: 16914585
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor.
    Liu G, He J, Dou S, Gupta S, Rusckowski M, Hnatowich DJ.
    Eur J Nucl Med Mol Imaging; 2005 Sep 15; 32(9):1115-23. PubMed ID: 16133391
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF.
    Liu G, Dou S, Pretorius PH, Liu X, Rusckowski M, Hnatowich DJ.
    Eur J Nucl Med Mol Imaging; 2008 Feb 15; 35(2):272-80. PubMed ID: 17909792
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.
    Liu G, Dou S, Chen X, Chen L, Liu X, Rusckowski M, Hnatowich DJ.
    Cancer Biother Radiopharm; 2010 Dec 15; 25(6):757-62. PubMed ID: 21204772
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting.
    Liu G, Dou S, He J, Yin D, Gupta S, Zhang S, Wang Y, Rusckowski M, Hnatowich DJ.
    Appl Radiat Isot; 2006 Sep 15; 64(9):971-8. PubMed ID: 16730997
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapy.
    Dou S, Smith M, Wang Y, Rusckowski M, Liu G.
    Cancer Biother Radiopharm; 2013 May 15; 28(4):335-42. PubMed ID: 23469942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.